0 Ovary 5 17.9 Pancreas 3 10.7

Colon 2 7.1 Prostate 2 7.1 Glioblastoma multiforme 1 3.6 AZD7762 clinical trial Hepatocellular carcinoma 1 3.6 Mesothelioma 1 3.6 Neuroendocrine 1 3.6 NSCLC 1 3.6 Oligodendroglioma 1 3.6 SCLC 1 3.6 Sarcoma 1 3.6 Thyroid 1 3.6 Prior systemic therapy     Yes 22 78.6 No 6 21.4 Once disease progression was observed, most Bioactive Compound Library patients elected to resume or initiate chemotherapy and/or targeted therapy. Seven (25%) patients requested to continue experimental treatment in combination with chemotherapy. Continuation of experimental treatment was allowed if desired by the patient and approved by the patient’s oncologist. Discovery of tumor-specific frequencies The exact duration of each examination was not recorded but lasted on average three hours. Each patient was examined an average of 3.3 ± 3.4 times (range 1 – 26). Frequency discovery was performed in patients with disease progression, stable disease or partial response. In general, we found more frequencies in patients with evidence SN-38 nmr of disease progression and large tumor bulk than in patients with stable disease, small tumor bulk or evidence of response. When we restrict the analysis of patients examined in 2006 and 2007, i.e. at a time when we had gathered more than 80% of the common tumor frequencies, we found that patients with evidence of disease progression had positive biofeedback responses to 70% or more of the frequencies previously discovered

in patients with the same disease. Conversely, patients with evidence of response to their current therapy had biofeedback responses to 20% or less

of the frequencies previously discovered in patients with the same disease. We also observed that patients examined on Methamphetamine repeated occasions developed biofeedback responses to an increasing number of tumor-specific frequencies over time whenever there was evidence of disease progression. Whenever feasible, all frequencies were individually retested at each frequency detection session. These findings suggest that a larger number of frequencies are identified at the time of disease progression. A total of 1524 frequencies ranging from 0.1 to 114 kHz were identified during a total of 467 frequency detection sessions (Table 1). The number of frequencies identified in each tumor type ranges from two for thymoma to 278 for ovarian cancer. Overall, 1183 (77.6%) of these frequencies were tumor-specific, i.e. they were only identified in patients with the same tumor type. The proportion of tumor-specific frequencies ranged from 56.7% for neuroendocrine tumors to 91.7% for renal cell cancer. A total of 341 (22.4%) frequencies were common to at least two different tumor types. The number of frequencies identified was not proportional to either the total number of patients studied or the number of frequency detection sessions (Table 1). Treatment with tumor-specific amplitude-modulated electromagnetic fields Twenty eight patients received a total of 278.4 months of experimental treatment.